Avacta Group PLC (LON:AVCT)
79.00p+4.64%
Spriggl Score: Poor— see the number + sub-scores with a free Spriggl account
Last 30 trading days
Spriggl AI Verdict
“Promising cancer science battles severe going concern risk; dilution threatens value despite strong clinical data.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About Avacta Group PLC
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. Its lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with kno…
- Sector:
- Healthcare
- Industry:
- Biotechnology
- Market Cap:
- £355.4M
Recent dividends
No recent dividends recorded.
Get the full Spriggl analysis — free
Sign up for a free Spriggl account to unlock the full Spriggl Score breakdown, screener, watchlist, and AI investment analysis on Avacta Group PLC and 1,600+ UK and US stocks.
Start free